-
Innovation Ranking
NewInnovation Ranking – Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company which focuses on the development of drugs for the treatment of light related severe skin disorders. The company’s lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other products under development includes CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC...
-
Company Insights
Innovation and Patenting activity of Clinuvel Pharmaceuticals Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Clinuvel Pharmaceuticals Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dezapelisib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dezapelisib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dezapelisib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Dezapelisib (INCB-40093)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octreotide LA in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details:...
-
Product Insights
Infantile Spasm (West Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Infantile Spasm (West Syndrome) - Drugs In Development, 2023’, provides an overview of the Infantile Spasm (West Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Porphyria (Erythropoietic Protoporphyri) – Drugs In Development, 2023
Global Markets Direct’s, ‘Porphyria (Erythropoietic Protoporphyri) - Drugs In Development, 2023’, provides an overview of the Porphyria (Erythropoietic Protoporphyri) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Vitiligo – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitiligo - Drugs In Development, 2023’, provides an overview of the Vitiligo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Childhood Epilepsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Childhood Epilepsy - Drugs In Development, 2023’, provides an overview of the Childhood Epilepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Childhood Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acute Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Acute Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...